Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia

Clin Cancer Res. 2020 Jan 15;26(2):325-327. doi: 10.1158/1078-0432.CCR-19-2975. Epub 2019 Oct 22.

Abstract

In December 2018, the FDA approved calaspargase pegol-mknl (Asperlas, Servier Pharmaceuticals) for acute lymphoblastic leukemia (ALL) in children and young adults up to age 21. Asparaginase is a critical component in the treatment of ALL, but the niche for calaspargase within current treatment protocols is unclear.See related article by Li et al., p. 328.

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Asparaginase*
  • Child
  • Humans
  • Polyethylene Glycols
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*
  • Young Adult

Substances

  • Polyethylene Glycols
  • Asparaginase
  • calaspargase pegol